- Conditions
- Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
- Interventions
- Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily
- Drug
- Lead sponsor
- University of Tennessee Medical Center
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
- Interventions
- Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 20
- States / cities
- La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
- Conditions
- Hypertension in Pregnancy
- Interventions
- Labetalol or Nifedipine
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 89 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
- Interventions
- Labetalol, Atenolol, Nifedipine
- Drug
- Lead sponsor
- Marshall University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Huntington, West Virginia
- Conditions
- Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum, Hypertensive Emergency
- Interventions
- Labetalol, Nifedipine
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Preeclampsia, Hypertension in Pregnancy
- Interventions
- Labetalol, Nifedipine
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pregnancy Toxemia, Hypertension, Proteinuria
- Interventions
- methyldopa, labetalol, nifedipine, clonidine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertension in Pregnancy, Preeclampsia
- Interventions
- Nifedipine, Labetalol
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Brooklyn, New York • New York, New York
- Conditions
- Hypertension, Postpartum Preeclampsia
- Interventions
- Nifedipine and Enalapril, Nifedipine and Labetalol
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypertension
- Interventions
- Anti-hypertensive therapy, No anti-hypertensive therapy (unless BP is severe)
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 2,408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
- Conditions
- Severe Postpartum Hypertension
- Interventions
- Labetalol, Nifedipine
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Elevated Blood Pressure, Pregnancy Induced Hypertension
- Interventions
- Nifedipine, Labetalol
- Drug
- Lead sponsor
- Marshall University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Huntington, West Virginia
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Postpartum Hypertension (PPHT)
- Interventions
- Labetalol, Nifedipine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Postpartum Complication, Maternal Hypertension, High Blood Pressure
- Interventions
- Oral Nifedipine, Oral Labetalol
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Obesity, Morbid, Preeclampsia
- Interventions
- Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Postpartum Preeclampsia, Hypertension in Pregnancy
- Interventions
- Labetalol Oral Tablet, NIFEdipine ER
- Drug
- Lead sponsor
- Nebraska Methodist Health System
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypertension in Pregnancy, Obstetrical Complications
- Interventions
- Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- 14 Years to 56 Years · Female only
- Enrollment
- 4,120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more